Acurx Pharmaceuticals, Inc. Retained Earnings
Acurx Pharmaceuticals, Inc. (ACXP) had Retained Earnings of -$79.22 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$79.22M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$76.97M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$75.29M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$73.71M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$79.22M 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$76.97M 10-Q · filed 2026-05-11 |
| 2025-12-31 | -$75.29M 10-Q · filed 2026-08-13 |
| 2025-09-30 | -$73.71M 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$71.72M 10-Q · filed 2025-08-11 |
| 2025-03-31 | -$69.47M 10-Q · filed 2025-05-12 |
| 2024-12-31 | -$67.32M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$64.54M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$61.72M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$57.60M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$53.22M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$48.10M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$44.99M 10-Q · filed 2023-08-11 |
| 2023-03-31 | -$41.54M 10-Q · filed 2023-05-12 |
| 2022-12-31 | -$38.64M 10-K · filed 2024-03-15 |
| 2022-09-30 | -$35.38M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$31.84M 10-Q · filed 2022-08-12 |
| 2022-03-31 | -$29.22M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$26.55M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$23.92M 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$19.28M 10-Q · filed 2021-08-13 |
| 2020-12-31 | -$13.80M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |